Journal
Blood Advances
Publication Date
9-12-2023
Volume
7
Issue
17
First Page
4926
Last Page
4935
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2022009260
Rights and Permissions
Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023 Sep 12;7(17):4926-4935. doi: 10.1182/bloodadvances.2022009260. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Bartlett, Nancy L and et al., "Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma." Blood Advances. 7, 17. 4926 - 4935. (2023).
https://digitalcommons.wustl.edu/oa_4/2197
Additional Links
Supplemental material is available for this article at publisher site.
